Wei-Qiang Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wei-Qiang Huang has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Dong-Xiao Wang
MD, Department of Cardiology, First Affiliated Hospital, Guang Xi Medical University, China. Manuscript preparation and writing
1 shared publication - Guo-Qiang Zhong
PhD, Department of Cardiology, First Affiliated Hospital, Guang Xi Medical University, China. Analysis and interpretation of data, technical procedures
1 shared publication - Jian-Jun Meng
MD, Geriatric Health Care Center, First Affiliated Hospital, Guang Xi Medical University, China. Critical revision
1 shared publication Qiaoling Yang
Department of Pharmacy and Central Laboratory Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital School of Medicine University of Electronic Science and Technology of China No. 32, West Second Section, First Ring Road Chengdu Sichuan 610072 P. R. China
1 shared publication- Qing-Jie Li
PhD, Department of Cardiology, Second Affiliated Hospital, Guang Xi Medical University, China. Analysis and interpretation of data, statistics analysis
1 shared publication - Rong-Hui Tu
PhD, Department of Geriatric Cardiology, First Affiliated Hospital, Guang Xi Medical University, China. Conception and design of the study, final approval
1 shared publication
Latest Publications
- 18 November 2024
- Published by Wiley in Advanced Therapeutics
- Vol. 8 (1)
Multifunctional Hydrogel Strategies for Myocardial Infarction: From Tissue Repair to Cardiac Regeneration
Myocardial infarction (MI) remains the leading cause of death in patients with cardiovascular disease worldwide, with therapeutic approaches predominantly relying on medication, medical device implantation, and organ transplantation, each constrained by inherent limitations. Injectable hydrogels have recently emerged as promising therapeutic tools, noted for their biocompatibility, injectability, and capacity to provide mechanical support crucial for myocardial tissue repair. This review aims to comprehensively explore the interaction between injectable hydrogels and myocardial repair post‐infarction. It encompasses recent advancements in various types of injectable hydrogels used in MI therapy, including those modulating microenvironments, conducting electricity, influencing immunomodulation, promoting angiogenesis, and improving ischemia‐reperfusion conditions. By synthesizing current research findings, this review facilitates interdisciplinary knowledge integration and the development of effective prognostic indicators for injectable materials.
- 18 November 2024
- Published by Wiley in Advanced Therapeutics
- Vol. 8 (1)
Multifunctional Hydrogel Strategies for Myocardial Infarction: From Tissue Repair to Cardiac Regeneration
Myocardial infarction (MI) remains the leading cause of death in patients with cardiovascular disease worldwide, with therapeutic approaches predominantly relying on medication, medical device implantation, and organ transplantation, each constrained by inherent limitations. Injectable hydrogels have recently emerged as promising therapeutic tools, noted for their biocompatibility, injectability, and capacity to provide mechanical support crucial for myocardial tissue repair. This review aims to comprehensively explore the interaction between injectable hydrogels and myocardial repair post‐infarction. It encompasses recent advancements in various types of injectable hydrogels used in MI therapy, including those modulating microenvironments, conducting electricity, influencing immunomodulation, promoting angiogenesis, and improving ischemia‐reperfusion conditions. By synthesizing current research findings, this review facilitates interdisciplinary knowledge integration and the development of effective prognostic indicators for injectable materials.
- Open Access
- 1 January 2020
- Published by FapUNIFESP (SciELO) in Acta Cirurgica Brasileira
- Vol. 35 (1) , e202000105
Involvement of HSP90 in ischemic postconditioning-induced cardioprotection by inhibition of the complement system, JNK and inflammation
To investigate whether heat shock protein 90 (HSP90) is involved in complement regulation in ischemic postconditioning (IPC). The left coronary artery of rats underwent 30 min of occlusion, followed by 120 min of reperfusion and treatment with IPC via 3 cycles of 30s reperfusion and 30s occlusion. The rats were injected intraperitoneally with 1 mg/kg HSP90 inhibitor geldanamycin (GA) after anesthesia. Eighty rats were randomly divided into four groups: sham, ischemia-reperfusion (I/R), IPC and IPC + GA. Myocardial infarct size, apoptosis index and the expression of HSP90, C3, C5a, tumor necrosis factor (TNF)-alpha, interleukin (IL)-1β and c-Jun N-terminal kinase (JNK) were assessed. Compared with the I/R injury, the IPC treatment significantly reduced infarct size, release of troponin T, creatine kinase-MB, and lactate dehydrogenase, and cardiomyocyte apoptosis. These beneficial effects were accompanied by a decrease in TNF-α, IL-1β, C3, C5a and JNK expression levels. However, all these effects were abrogated by administration of the HSP90 inhibitor GA. HSP90 exerts a profound effect on IPC cardioprotection, and may be linked to the inhibition of the complement system and JNK, ultimately attenuating I/R-induced myocardial injury and apoptosis.
- 1 January 2020
- Published by FapUNIFESP (SciELO) in Acta Cirurgica Brasileira
- Vol. 35 (1) , e202000105
Open AccessInvolvement of HSP90 in ischemic postconditioning-induced cardioprotection by inhibition of the complement system, JNK and inflammation
To investigate whether heat shock protein 90 (HSP90) is involved in complement regulation in ischemic postconditioning (IPC). The left coronary artery of rats underwent 30 min of occlusion, followed by 120 min of reperfusion and treatment with IPC via 3 cycles of 30s reperfusion and 30s occlusion. The rats were injected intraperitoneally with 1 mg/kg HSP90 inhibitor geldanamycin (GA) after anesthesia. Eighty rats were randomly divided into four groups: sham, ischemia-reperfusion (I/R), IPC and IPC + GA. Myocardial infarct size, apoptosis index and the expression of HSP90, C3, C5a, tumor necrosis factor (TNF)-alpha, interleukin (IL)-1β and c-Jun N-terminal kinase (JNK) were assessed. Compared with the I/R injury, the IPC treatment significantly reduced infarct size, release of troponin T, creatine kinase-MB, and lactate dehydrogenase, and cardiomyocyte apoptosis. These beneficial effects were accompanied by a decrease in TNF-α, IL-1β, C3, C5a and JNK expression levels. However, all these effects were abrogated by administration of the HSP90 inhibitor GA. HSP90 exerts a profound effect on IPC cardioprotection, and may be linked to the inhibition of the complement system and JNK, ultimately attenuating I/R-induced myocardial injury and apoptosis.